Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 439

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration

Open access
Meyers, Rebecka L, Maibach, Rudolf, Hiyama, Eiso, Häberle, Beate, Krailo, Mark, Rangaswami, Arun, Aronson, Daniel C, Malogolowkin, Marcio H, Perilongo, Giorgio, von Schweinitz, Dietrich, Ansari, Marc, Lopez-Terrada, Dolores, Tanaka, Yukichi, Alaggio, Rita, Leuschner, Ivo, Hishiki, Tomoro, Schmid, Irene, Watanabe, Kenichiro, Yoshimura, Kenichi, Feng, Yurong, Rinaldi, Eugenia, Saraceno, Davide, Derosa, Marisa, Czauderna, Piotr·2017·The Lancet Oncology

Abstract

Summary Background Comparative assessment of treatment results in paediatric hepatoblastoma trials has been hampered by small patient numbers and the use of multiple disparate staging systems by the four major trial groups. To address this challenge, we formed a global coalition, the Children’s Hepatic tumors International Collaboration (CHIC), with the aim of creating a common approach to staging and risk stratification in this rare cancer. Methods The CHIC steering committee—consisting of leadership from the four major cooperative trial groups (the International Childhood Liver Tumours Strategy Group, Children’s Oncology Group, the German Society for Paediatric Oncology and Haematology, and the Japanese Study Group for Paediatric Liver Tumours)—created a shared international database that includes comprehensive data from 1605 children treated in eight multicentre hepatoblastoma trials over 25 years. Diagnostic factors found to be most prognostic on initial analysis were PRETreatment EXTent of disease (PRETEXT) group; age younger than 3 years, 3–7 years, and 8 years or older; α fetoprotein (AFP) concentration of 100 ng/mL or lower and 101–1000 ng/mL; and the PRETEXT annotation factors metastatic disease (M), macrovascular involvement of all hepatic veins (V) or portal bifurcation (P), contiguous extrahepatic tumour (E), multifocal tumour (F), and spontaneous rupture (R). We defined five clinically relevant backbone groups on the basis of established prognostic factors: PRETEXT I/II, PRETEXT III, PRETEXT IV, metastatic disease, and AFP concentration of 100 ng/mL or lower at diagnosis. We then carried the additional factors into a hierarchical backwards elimination multivariable analysis and used the results to create a new international staging system. Findings Within each backbone group, we identified constellations of factors that were most predictive of outcome in that group. The robustness of candidate models was then interrogated using the bootstrapping procedure. Using the clinically established PRETEXT groups I, II, III, and IV as our stems, we created risk stratification trees based on 5 year event-free survival and clinical applicability. We defined and adopted four risk groups: very low, low, intermediate, and high. Interpretation We have created a unified global approach to risk stratification in children with hepatoblastoma on the basis of rigorous statistical interrogation of what is, to the best of our knowledge, the largest dataset ever assembled for this rare paediatric tumour. This achievement provides the structural framework for further collaboration and prospective international cooperative study, such as the Paediatric Hepatic International Tumour Trial (PHITT). Funding European Network for Cancer Research in Children and Adolescents, funded through the Framework Program 7 of the European Commission (grant number 261474); Children’s Oncology Group CureSearch grant contributed by the Hepatoblastoma Foundation; Practical Research for Innovative Cancer Control and Project Promoting Clinical Trials for Development of New Drugs and Medical Devices, Japan Agency for Medical Research; and Swiss Cancer Research grant.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(16)30598-8

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 439

Metadata

Authors
Meyers, R. L., Maibach, R., Hiyama, E., Häberle, B., Krailo, M., Rangaswami, A., Aronson, D. C., Malogolowkin, M. H., Perilongo, G., von Schweinitz, D., Ansari, M., Lopez-Terrada, D., Tanaka, Y., Alaggio, R., Leuschner, I., Hishiki, T., Schmid, I., Watanabe, K., Yoshimura, K., Feng, Y., Rinaldi, E., Saraceno, D., Derosa, M., & Czauderna, P.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2017-01
Volume
18
Issue
1
Pages
122-131
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2549880782
Cited by
439
References
10
FWCI
15.58
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration. https://app.cochat.ai/papers/10.1016/s1470-2045(16)30598-8
The paper
Meyers, R. L., Maibach, R., Hiyama, E., Häberle, B., Krailo, M., Rangaswami, A., Aronson, D. C., Malogolowkin, M. H., Perilongo, G., von Schweinitz, D., Ansari, M., Lopez-Terrada, D., Tanaka, Y., Alaggio, R., Leuschner, I., Hishiki, T., Schmid, I., Watanabe, K., Yoshimura, K., . . . Czauderna, P. (2017). Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(16)30598-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.